Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 6/2017

01-12-2017

Possible Role of IL-25 in Eosinophilic Lung Inflammation in Patients with Chronic Eosinophilic Pneumonia

Authors: Shigeki Katoh, Masaki Ikeda, Nobuhiro Matsumoto, Hiroki Shimizu, Masaaki Abe, Yoshihiro Ohue, Keiji Mouri, Yoshihiro Kobashi, Masamitsu Nakazato, Mikio Oka

Published in: Lung | Issue 6/2017

Login to get access

Abstract

Purpose

Interleukin (IL)-25 and IL-33 induce IL-5 production by various types of cells, such as type 2 helper T (Th2) cells and type 2 innate lymphoid cells. The number of Th2 cells and concentration of IL-5 in the bronchoalveolar lavage fluid (BALF) are increased in patients with eosinophilic pneumonia (EP). To examine the contribution of IL-25 and IL-33 to eosinophilic inflammation of the lung in humans, we evaluated IL-5, IL-25 and IL-33 levels in the BALF of patients with EP.

Methods

IL-5, IL-25, and IL-33 concentrations in the BALF were measured by enzyme-linked immunosorbent assay in patients with acute eosinophilic pneumonia (AEP), chronic eosinophilic pneumonia (CEP), idiopathic pulmonary fibrosis (IPF), and sarcoidosis.

Results

The absolute number of eosinophils, and IL-5 levels, but not IL-33 levels, in the BALF were significantly higher in patients with EP than in patients with IPF and sarcoidosis. IL-25 levels in the BALF were significantly higher in patients with CEP, but not in patients with AEP, than in patients with IPF and sarcoidosis. The absolute number of eosinophils was significantly correlated with the IL-5 concentration in the BALF of patients with EP. IL-5 concentrations were significantly correlated with IL-25 concentrations in the BALF of patients with CEP, but not in patients with AEP. IL-5 levels were not correlated with IL-33 levels in the BALF of patients with EP.

Conclusions

Our findings suggest that IL-25 plays an important role via IL-5 in eosinophilic lung inflammation in patients with CEP.
Literature
1.
2.
3.
Marchand E, Cordier JF (2006) Idiopathic chronic eosinophilic pneumonia. Semin Respir Crit Care Med 27:134–141CrossRefPubMed
4.
Katoh S, Taniguchi H, Matsubara Y et al (1999) Overexpression of CD44 on alveolar eosinophils with high concentrations of soluble CD44 in bronchoalveolar lavage fluid in patients with eosinophilic pneumonia. Allergy 54:1286–1292CrossRefPubMed
5.
Katoh S, Matsumoto N, Matsumoto K et al (2004) Elevated interleukin-18 levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. Allergy 59:850–856CrossRefPubMed
6.
Katoh S, Fukushima K, Matsumoto N et al (2003) Accumulation of CCR4-expressing CD4 + T cells and high concentration of its ligands (TARC and MDC) in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. Allergy 58:518–523CrossRefPubMed
7.
Iwakura Y, Ishigame H, Saijo S et al (2011) Functional specialization of interleukin-17 family members. Immunity 34:149–162CrossRefPubMed
8.
9.
Ziegier SF (2012) Thymic stromal lymphopoietin and allergic disease. J Allergy Clin Immunol 130:845–852CrossRef
10.
Ikutani M, Yanagibashi T, Ogasawara M et al (2012) Identification of innate IL-5-producing cells and their role in lung eosinophils regulating and antitumor immunity. J Immunol 188:703–713CrossRefPubMed
11.
Halim TYF, Krauss RH, Sun AC et al (2012) Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 36:451–463CrossRefPubMed
12.
Yasuda K, Muto T, Kawagoe T et al (2012) Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc Natl Acad Sci 109:3451–3456CrossRefPubMedPubMedCentral
13.
Brusselle GG, Maes T, Bracke KR (2013) Eosinophilic airway inflammation in nonallergic asthma. Nat Med 19:977–979CrossRefPubMed
14.
Yu S, Kim HY, Chang Y-J et al (2014) Innate lymphoid cells and asthma. J Allergy Clin Immunol 133:943–950CrossRefPubMed
15.
Travis WD, Costabel U, Hansell DM et al (2013) ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American thoracic society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188:733–748CrossRefPubMed
16.
Katoh S, Matsumoto N, Fukushima K et al (2000) Elevated chemokines levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. J Allergy Clin Immunol 106:730–736CrossRefPubMed
17.
Valizadeh A, Khosravi A, Zadeh LJ et al (2015) Role of IL-25 in immunity. J Clin Diag Res 9(4):OE01–OE04
18.
Tang W, Smith SG, Beaudin S et al (2014) IL-25 and IL-25 receptor expression on eosinophils from subjects with allergic asthma. Int Arch Allergy Immunol 163:5–10CrossRefPubMed
19.
Terrier B, Bieche I, Maisonobe T et al (2010) Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg–Strauss syndrome. Blood 116:4523–4531CrossRefPubMed
20.
21.
Liu B, Lee J-B, Chen C-Y et al (2015) Collaborative interactions between type 2 innate lymphoid cells and antigen-specific CD4 + Th2 cells exacerbate murine allergic airway diseases with prominent eosinophilia. J Immunol 194:3583–3593CrossRefPubMedPubMedCentral
22.
Kamijo S, Takeda H, Tokura T et al (2013) IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. J Immunol 190:4489–4499PubMed
23.
Barlow JL, Peel S, Fox J et al (2013) IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J Allergy Clin Immunol 132:933–941CrossRefPubMed
24.
Kim H-R, Jun C-D, Lee Y-J et al (2010) Levels of circulating IL-33 and eosinophil cationic protein in patients with hypereosinophilia or pulmonary eosinophilia. J Allergy Clin Immunol 126:880–882CrossRefPubMed
25.
Mato N, Bando M, Kusano A et al (2013) Clinical significance of interleukin 33 (IL-33) in patients with eosinophilic pneumonia. Allergol Int 62:45–52CrossRefPubMed
26.
Jeong YJ, Kim K-I, Seo IJ et al (2007) Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. RadioGraphics 27:617–639CrossRefPubMed
Metadata
Title
Possible Role of IL-25 in Eosinophilic Lung Inflammation in Patients with Chronic Eosinophilic Pneumonia
Authors
Shigeki Katoh
Masaki Ikeda
Nobuhiro Matsumoto
Hiroki Shimizu
Masaaki Abe
Yoshihiro Ohue
Keiji Mouri
Yoshihiro Kobashi
Masamitsu Nakazato
Mikio Oka
Publication date
01-12-2017
Publisher
Springer US
Published in
Lung / Issue 6/2017
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-017-0048-8

Other articles of this Issue 6/2017

Lung 6/2017 Go to the issue

COPD

IL-8 Gene Variants and Expression in Childhood Asthma

PULMONARY VASCULAR DISEASE

“Pulmonary Vein Sign” for Pulmonary Embolism Diagnosis in Computed Tomography Angiography

COPD

Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies

COPD

The Influence of Body Composition on Pulmonary Rehabilitation Outcomes in Chronic Obstructive Pulmonary Disease Patients

OriginalPaper

Diet and Respiratory Health in Children from 11 Latin American Countries: Evidence from ISAAC Phase III

OriginalPaper

Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits